An Ovarian Cancer Roundtable: The Role of PARP Inhibitors in the Treatment of Advanced Disease

An Ovarian Cancer Roundtable: The Role of PARP Inhibitors in the Treatment of Advanced Disease

A panel of three experts, led by Dr. Brian Slomovitz of Sylvester Comprehensive Cancer Center, University of Miami Health System, discussed the expanded role of PARP inhibitors and how the new targeted agents, niraparib, olaparib, and rucaparib, are setting a new paradigm in the treatment of advanced ovarian cancer. Topics covered included a look at three landmark trials from ESMO and how they've influenced treatment regimens, incorporating BRCA and HRD testing on patients, and sequencing PARP inhibitors with and without bevacizumab as part of treatment.